EARLY RESPONSE AND GENETICS DEFINE RELAPSE RISK AFTER FRONTLINE BLINATUMOMAB IN CHILDHOOD B-ALL: A COHORT STUDY. (PubMed, Blood Adv) - Sep 2, 2026 - "Relapse following frontline blinatumomab is determined by early treatment response and genetic subtype rather than conventional chemotherapy-derived risk factors. These findings support immunotherapy-specific risk stratification to guide treatment intensity."
Journal • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Childhood B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • DUX4 • IKZF1
|
|
Ajay Vora; Alison Spence; Amir Enshaei; Andrea Malone; Andrew King; Angus Hodder; Anna Castleton; Anthony V Moorman; Bethany Rose Mitchell; Christopher Dalley; Clare Rowntree; Danielle Ingham; David Devenney; David O'Connor; Denise Kathleen Bonney; Emma K Nicholson; Galina Jigoulina; Ismail Elbeshlawi; Jayashree Motwani; Jeremy P Hancock; John Moppett; Jude Gibson; Kaljit Bhuller; Katharine Hodby; Katharine Patrick; Katherine Clesham; Katherine Lindsay; Lindsay C George; Majid Madni; Michael Gattens; Miguel Vieira Martins; Philip Connor; Rachael E Hough; Sanjay Tewari; Stuart Paul Adams; Subramaniam Ramanathan; Sujith Samarasinghe; Susan Baird; Yang Yang Wang
|